- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05077267
ABNCoV2 Vaccine in SARS-CoV-2 (COVID-19) Seronegative and Seropositive Adult Subjects
An Open Label Phase 2 Trial to Evaluate the Safety, Tolerability and Immunogenicity of the ABNCoV2 Vaccine in SARS-CoV-2 Seronegative and Seropositive Adult Subjects
연구 개요
상세 설명
For this Phase 2 trial ABNCoV2-01, in a run in phase 6 adults (comprising of 3 subjects in each Group 1 and 2) will be vaccinated at 1 clinical trial site in a consecutive manner, with an at least 48 hours interval between the first and second subject of each group, then the second and third subject dosed on consecutive days, before opening up to full enrolment of the trial. Safety assessments will be based on solicited and unsolicited AE data (first week after vaccination) evaluated by an independent Data Monitoring Committee (DMC). After a positive DMC recommendation, enrolment to the rest of Group 1 and 2 of the trial will commence. Group 3 subjects will be enrolled after completion of Group 2 enrollment.
This phase 2 trial will evaluate a homologous prime-boost regimen with 100 µg ABNCoV2 in initially seronegative adult subjects (Group 1), as determined by a qualitative test for SARS-CoV-2 antibodies, compared to a single boost vaccination with 100 µg (Group 2) and 50 µg (Group 3) ABNCoV2 in initially seropositive subjects, as defined by a positive qualitative test for SARS-CoV-2 antibodies and either a history of SARS-CoV-2 vaccination or previous COVID-19 disease (Group 2 and 3) at least 90 days prior to planned trial vaccination.
Due to the timing of the addition of Group 3, enrollment into Group 2 will be completed prior to enrolling subjects into Group 3. Therefore, no randomization will be required for the seropositive subjects.
연구 유형
등록 (실제)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
-
Berlin, 독일, 10629
- emovis GmbH
-
Hamburg, 독일, 22143
- Velocity Clinical Research Hamburg
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Seronegative (Group 1): negative qualitative test for SARS-CoV-2 antibodies at SCR.
Seropositive (Group 2 and Group 3): Previous COVID-19 disease or previously completed vaccination regimen with an authorized SARS-CoV-2 vaccine at least 90 days before planned trial vaccination and a positive qualitative test for SARS-CoV-2 antibodies at SCR. "Authorized" SARS-CoV-2 vaccine refers to authorization status at SCR, i.e., subjects can be eligible if the subject previously received investigational vaccines that have since been authorized for emergency use or granted full market licensure. Receipt of a single dose of an authorized COVID-19 vaccine regimen in subjects with a previous diagnosis of COVID-19 or a mix/match series of 2 doses of any authorized COVID-19 vaccine will be considered as a completed vaccination.
- General good health, without acute medical illness, physical exam findings, or laboratory abnormalities, as determined by the investigator.
- Body mass index (BMI) ≥18.5 and <40.
- Female subjects of childbearing potential (WOCBP) must agree to the use of an effective method of birth control from at least 30 days prior to administration of the vaccine until 30 days after the vaccination. Male subjects who are sexually active with a WOCBP must agree to the use of an effective method of birth control from the day of administration of the vaccine until 30 days after the vaccination.
- Negative human immunodeficiency virus antibody test (anti HIV), negative hepatitis B surface antigen (HBsAG) and negative antibody to hepatitis C virus (HCV).
Exclusion Criteria:
• Group 1 only: History of COVID-19 infection or previous vaccination with a licensed or candidate SARS-CoV-2 vaccine, or positive qualitative test for SARS-CoV-2 antibodies at SCR.
Groups 2 and 3 only: History of COVID-19 infection and subsequent receipt of more than one licensed or candidate SARS-CoV-2 vaccine.
- Positive test for SARS-CoV-2 infection at SCR.
- Pregnant or breastfeeding women.
- Subject has an acute or chronic medical condition that, in the opinion of the investigator, would render the trial procedures unsafe or would interfere with the evaluation of the responses.
- History of or active autoimmune disease. History of Guillain-Barré syndrome or Reye's syndrome. Persons with vitiligo or thyroid disease taking thyroid replacement are not excluded.
- Known or suspected impairment of immunologic functions including, but not limited to, known immunodeficiency syndrome.
- History of malignancy other than squamous cell or basal cell skin cancer, unless there has been surgical excision at least 6 months prior to SCR that is considered to have achieved cure. Subjects with history of skin cancer must not be vaccinated at the previous tumor site.
- Laboratory parameters (such as complete blood count, serum biochemistry including aspartate aminotransferase [AST], alanine amino transferase [ALT], alkaline phosphokinase [AP], bilirubin, or creatinine values), pulse rate, blood pressure, or electrocardiogram (ECG) outside normal range at SCR and deemed clinically relevant by the investigator.
- Clinically significant mental disorder not adequately controlled by medical treatment.
- Active or recent history (within 6 months before SCR) of chronic alcohol abuse, intravenous drug abuse, or nasal drug abuse.
- History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
- History of anaphylaxis or severe allergic reaction to any vaccine.
- Having received any vaccinations or planned vaccinations with a live vaccine within 30 days prior to or after trial vaccination.
- Having received any vaccinations or planned vaccinations with an inactivated vaccine within 14 days prior to or after trial vaccination.
- Recent blood donation (including platelets, plasma and red blood cells) within 4 weeks prior to SCR, or planned blood donations during the active trial phase.
- Chronic systemic administration (defined as more than 14 days of >5 mg prednisone [or equivalent]/day), or any other immune-modifying drugs during a period starting 3 months prior to administration of the vaccine and ending 4 weeks after the last vaccination. The use of topical, inhaled, ophthalmic and nasal glucocorticoids is allowed.
- Post organ transplant subjects, whether or not receiving chronic immunosuppressive therapy.
- Administration or planned administration of immunoglobulins and/or any blood products during a period starting 3 months prior to administration of the vaccine and ending 4 weeks after the last vaccination. Receipt of packed red blood cells given for an emergency indication in an otherwise healthy person, and not required as ongoing treatment is not exclusionary (for example packed red blood cells given in emergency during an elective surgery).
- Use of any investigational or non-registered drug or vaccine other than the trial vaccine within 30 days preceding the administration of trial vaccine, or planned administration of such a drug or vaccine throughout the trial.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: ABNCoV2 100ug single dose
ABNCoV2 100ug single dose.
Intervention type: Biological/Vaccine
|
IM injection 100ug dose
|
실험적: ABNCoV2 50ug single dose
ABNCoV2 50ug single dose.
Intervention type: Biological/Vaccine
|
IM injection 50ug dose
|
실험적: ABNCoV2 100ug two doses
ABNCoV2 100ug two doses 4 weeks apart.
Intervention type: Biological/Vaccine
|
IM injection 100ug dose
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
SARS-CoV-2 neutralizing antibody titers
기간: 2 weeks after the last vaccination, i.e., after the second vaccination in initially seronegative subjects and after the single boost vaccination in initially seropositive subjects.
|
SARS-CoV-2 neutralizing antibody titers
|
2 weeks after the last vaccination, i.e., after the second vaccination in initially seronegative subjects and after the single boost vaccination in initially seropositive subjects.
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Subjects reporting any SAEs or AESIs assessed as related to trial vaccine.
기간: Within 8 days after vaccination
|
Subjects reporting any SAEs or AESIs assessed as related to trial vaccine.
|
Within 8 days after vaccination
|
Subjects reporting any Grade 3 or higher AEs assessed as related to trial vaccine.
기간: 8 days after vaccination
|
Subjects reporting any Grade 3 or higher AEs assessed as related to trial vaccine.
|
8 days after vaccination
|
공동 작업자 및 조사자
스폰서
수사관
- 수석 연구원: Christine Grigat, MD, Velocity Clinical Research Hamburg
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- ABNCoV2-01
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
COVID-19 질병에 대한 임상 시험
-
Yang I. Pachankis모집하지 않고 적극적으로COVID-19 호흡기 감염 | COVID-19 스트레스 증후군 | COVID-19 백신 부작용 | COVID-19 관련 혈전색전증 | COVID-19 집중 치료 후 증후군 | COVID-19 관련 뇌졸중중국
-
Endourage, LLC모병긴 COVID | 긴 Covid19 | 포스트 급성 COVID-19 | 장거리 COVID | 장거리 COVID-19 | COVID-19 후 증후군미국
-
Massachusetts General Hospital모병
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of Ioannina모병COVID-19 폐렴 | COVID-19 호흡기 감염 | 코로나19 감염병 세계적 유행 | COVID-19 급성호흡곤란증후군 | COVID-19 관련 폐렴 | COVID 19 관련 응고병증 | COVID-19(코로나바이러스 질병 2019) | COVID-19 관련 혈전색전증그리스
-
Jonathann Kuo, MD모집하지 않고 적극적으로SARS-CoV2 감염 | 코로나19 이후 증후군 | 자율신경실조증 | 급성 COVID-19 후 증후군 | 긴 COVID | 긴 Covid19 | COVID-19 재발 | 포스트 급성 COVID-19 | 급성 COVID-19 감염 후 | COVID-19의 급성 후유증 | 자율신경실조증 유사 장애 | 자율신경실조증 기립성 저혈압 증후군 | COVID-19 이후 상태 | 포스트 코로나 증후군 | COVID-19 이후 상태, 지정되지 않음미국
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention...완전한
-
Patrick Robinson모병코로나19 | COVID-19 폐렴 | COVID-19 호흡기 감염 | COVID-19 급성 기관지염미국
-
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.완전한
ABNCoV2 100ug에 대한 임상 시험
-
Radboud University Medical CenterEuropean Union완전한
-
Imperial College LondonEuropean Commission빼는
-
Seoul National University HospitalGreen Cross Corporation; LSK Global Pharma Services Co. Ltd.완전한
-
Tampere University HospitalOrion Corporation, Orion Pharma모집하지 않고 적극적으로